Journal
AMERICAN JOURNAL OF HYPERTENSION
Volume 34, Issue 5, Pages 531-539Publisher
OXFORD UNIV PRESS
DOI: 10.1093/ajh/hpaa192
Keywords
blood pressure; blood pressure targets; drug therapy; hypertension; prevention
Categories
Funding
- Novartis Pharmaceuticals
Ask authors/readers for more resources
Combination therapy of a CCB with an ACEI is more effective in preventing cardiovascular events compared to combination therapy with HCTZ and an ACEI, especially in patients with aggressive systolic BP targets and those with resistant hypertension.
BACKGROUND The 2017 hypertension guidelines lowered systolic blood pressure (BP) goals to <130 mm Hg and redefined resistant hypertension. We investigated if these changes alter the cardiovascular benefits demonstrated by combining a calcium channel blocker (CCB), rather than hydrochlorothiazide (HCTZ), with an angiotensin-converting enzyme inhibitor (ACEI). METHODS In this post hoc analysis of the Avoiding Cardiovascular Events Through Combination Therapy in Patients Living with Systolic Hypertension trial (n = 11,506), we compared the primary composite outcome (cardiovascular death, myocardial infarction, stroke, hospitalization for angina, resuscitation after sudden cardiac death, and coronary revascularization) between the 2 combination-treatment limbs in patients achieving a systolic BP <= 130 mm Hg and those with apparent resistant hypertension (prescribed >= 4 antihypertensive medications). RESULTS Among study patients, 5,221 (45.4%) achieved a systolic BP <= 130 mm Hg. There were fewer primary endpoints in the amlodipine/benazepril (9.2%) vs. the HCTZ/benazepril (10.9%) limb (adjusted hazard ratio [HR] 0.83, 95% confidence interval [CI], 0.70-0.99). There were also fewer primary endpoints in the amlodipine/benazepril (12.8%) vs. the HCTZ/benazepril (15.2%) limb (n = 4,451, 38.7%) among patients with apparent resistant hypertension (HR 0.81, 95% CI, 0.70-0.95). CONCLUSIONS Combination therapy adding a CCB, rather than HCTZ, to an ACEI was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic BP targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available